MTNB News Alert Matinas Biopharma Hl (MTNB) 0.4600 12/25/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Matinas Biopharma Hl (MTNB) 0.4600 $MTNB

Matinas BioPharma Provides Update on Clinical Development Program for MAT9001 Following FDA Feedback on IND Submission
GlobeNewswire - Tue Dec 23, 7:05AM CST
Matinas BioPharma Holdings, Inc. ("Matinas BioPharma" or the "Company" (OTCQB:MTNB), an emerging biopharmaceutical company focused on the development and commercialization of omega-3 fatty acid-based prescription therapeutics for the treatment of cardiovascular and metabolic conditions, announced today that the Company has received advice and recommendations from the United States Food and Drug Administration (FDA) on its Investigational New Drug Application (IND) for its product candidate, MAT9001.

Eight Companies Webcast Live to Investors, December 4th at VirtualInvestorConferences.com
PR Newswire - Tue Dec 02, 7:29AM CST
CEOs and top executives to take questions in real-time during formal roadshow presentations as well as meet and "chat" in virtual trade booths
SMLR: 2.06 (-0.08), ONVO: 6.84 (+0.03), CYTX: 0.48 (-0.01), IAG: 2.41 (+0.06)

Matinas BioPharma Appoints Leading Clinical Lipid Specialist and Metabolism Researcher, Kevin C. Maki, Ph.D., to Scientific Advisory Board
GlobeNewswire - Mon Nov 24, 6:05AM CST
Matinas BioPharma Holdings, Inc. ("Matinas BioPharma" or the "Company" (OTCQB:MTNB), an emerging biopharmaceutical company focused on the development and commercialization of omega-3 fatty acid-based prescription therapeutics for the treatment of cardiovascular and metabolic conditions, announced today that it has appointed Kevin C. Maki, Ph.D. to its recently formed Scientific Advisory Board (SAB).

Matinas BioPharma to Present at Two Investor Conferences in Early December
GlobeNewswire - Thu Nov 20, 9:12AM CST
- LD Micro Main Event VII Presentation and Live Audio Webcast on Wednesday, December 3, 2014, at 3:00 p.m. PST / 6:00 p.m. EST -

Matinas BioPharma Commences Dosing in First Human Trial of Lead Product Candidate MAT9001
GlobeNewswire - Wed Nov 12, 6:35AM CST
Matinas BioPharma Holdings, Inc. ("Matinas BioPharma" or the "Company" (OTCQB:MTNB), an emerging biopharmaceutical company focused on the development and commercialization of omega-3 fatty acid-based prescription therapeutics for the treatment of cardiovascular and metabolic conditions, today announced it has commenced dosing in the first-in-human study of MAT9001. The Company's initial trial is being conducted in Canada and is a pharmacokinetic and pharmacodynamic (PK/PD) study of MAT9001 versus an active comparator.

Matinas Biopharma Receives Notice of Allowance of U.S. Patent for MAT9001
GlobeNewswire - Mon Nov 10, 6:35AM CST
Matinas BioPharma Holdings, Inc. ("Matinas BioPharma" or the "Company" (OTCQB:MTNB), an emerging biopharmaceutical company focused on the development and commercialization of omega-3 fatty acid-based prescription therapeutics for the treatment of cardiovascular and metabolic conditions, today announced it received a Notice of Allowance from the U.S. Patent and Trademark Office ("USPTO" for U.S. Patent Application Serial No. 14/101,165 entitled, "Methods of Administering Compositions Comprising Docosapentaenoic Acid." Upon issuance, the patent will provide intellectual property protection through 2033.

Matinas BioPharma Appoints Cardiologist and Lipidology Expert Christie M. Ballantyne, M.D. to Scientific Advisory Board
GlobeNewswire - Tue Nov 04, 6:39AM CST
Matinas BioPharma Holdings, Inc. ("Matinas BioPharma" or the "Company" (OTCQB:MTNB), an emerging biopharmaceutical company focused on the development and commercialization of omega-3 fatty acid-based prescription therapeutics for the treatment of cardiovascular and metabolic conditions, today announced that it has established a new Scientific Advisory Board (SAB) and appointed internationally renowned cardiologist Christie M. Ballantyne, M.D., as its first SAB member. The Company expects to add additional SAB members over the coming months.

Matinas BioPharma Receives Authorization From Health Canada to Initiate Human Clinical Study of Lead Product Candidate MAT9001
GlobeNewswire - Wed Oct 29, 6:35AM CDT
Matinas BioPharma Holdings, Inc. ("Matinas BioPharma" or the "Company" (OTCQB:MTNB), an emerging biopharmaceutical company focused on the development and commercialization of omega-3 fatty acid-based prescription therapeutics for the treatment of cardiovascular and metabolic conditions, today announced that it has received a Notice of Authorization from Health Canada to initiate the first-in-human study of MAT9001. The Company expects to commence dosing in this pharmacokinetic and pharmacodynamic (PK/PD) study of MAT9001 in Canada during the fourth quarter of 2014 and report topline data in the second quarter of 2015.

Matinas BioPharma Submits Investigational New Drug Application for Lead Product Candidate MAT9001 for the Treatment of Severe Hypertriglyceridemia
GlobeNewswire - Mon Oct 20, 8:38AM CDT
Matinas BioPharma Holdings, Inc. ("Matinas BioPharma" or the "Company" (OTCQB:MTNB), an emerging biopharmaceutical company focused on the development and commercialization of omega-3 fatty acid-based prescription therapeutics for the treatment of cardiovascular and metabolic conditions, announced today that the Company has submitted an Investigational New Drug application (IND) for MAT9001 to the United States Food and Drug Administration (FDA).

Matinas BioPharma to Present at the 13th Annual BIO Investor Forum on Wednesday, October 8, 2014
GlobeNewswire - Tue Sep 30, 6:35AM CDT
Matinas BioPharma Holdings, Inc. ("Matinas BioPharma" or the "Company" (OTCQB:MTNB), an emerging biopharmaceutical company focused on the development and commercialization of omega-3 fatty acid-based prescription therapeutics for the treatment of cardiovascular and metabolic conditions, today announced that Roelof Rongen, President and Chief Executive Officer, will be presenting at the 13th Annual BIO Investor Forum being held October 7-8, 2014 at the Palace Hotel in San Francisco, California. The annual BIO Investor Forum is hosted by the Biotechnology Industry Organization (BIO) and features leading private and emerging public companies.

Matinas BioPharma - "Clinical Treatment Guidelines for Dyslipidemia Continue to Evolve"
ACCESSWIRE - Mon Sep 29, 9:30AM CDT
New York, NY / September 29, 2014 / Matinas BioPharma Holdings, Inc. (OTCQB: MTNB) today published a new blog post on The Chairman's Blog, written by the Company's President and Chief Executive Officer, Roelof Rongen. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.

SeeThruEquity Announces Fall Microcap Investor Conference To Be Held September 11, 2014
ACCESSWIRE - Mon Sep 08, 4:27PM CDT
Conference Being Held at Convene Times Square in Midtown

SeeThruEquity Fall Microcap Investor Conference To Be Held September 11, 2014
ACCESSWIRE - Mon Sep 08, 8:13AM CDT
Conference Being Held at Convene Times Square in Midtown

Matinas BioPharma Holdings, Inc. Approved to Trade on OTCQB Venture Stage Marketplace
GlobeNewswire - Mon Sep 08, 6:36AM CDT
Matinas BioPharma Holdings, Inc. ("Matinas BioPharma" or the "Company" (OTCQB:MTNB), an emerging biopharmaceutical company focused on the development and commercialization of omega-3 fatty acid-based prescription therapeutics for the treatment of cardiovascular and metabolic conditions, today announced it has been approved to continue quotation of its securities on OTCQB, the venture stage marketplace (the "OTCQB" , effective as of September 5, 2014. The Company's shares will continue to trade under the ticker symbol "MTNB."

Matinas BioPharma to Present at Three Investor Conferences in September
GlobeNewswire - Thu Sep 04, 6:05AM CDT
- Rodman & Renshaw 16 Annual Global Investment Presentation and Live Audio Webcast on September 9, 2014 -

S&P Capital IQ Initiates Coverage on Matinas BioPharma Holdings, Inc. in S&P Capital IQ Factual Stock Reports
PR Newswire - Wed Sep 03, 8:38AM CDT
S&P Capital IQ (MHFI) announced today that it has commenced Factual Stock Report coverage on Matinas BioPharma Holdings, Inc.
MHFI: 90.70 (+0.34)

SeeThruEquity Initiates Research Coverage on Matinas BioPharma Holdings, Inc. with Target Price of $3.78
ACCESSWIRE - Wed Sep 03, 8:09AM CDT
New York, NY / ACCESSWIRE / September 3, 2014 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has initiated coverage on Matinas BioPharma Holdings, Inc. (OTCBB: MTNB), a development stage biopharmaceutical company, founded in 2011, with a focus on identifying and developing novel pharmaceutical products for the treatment of abnormalities in blood lipids, referred to as dyslipidemia, and the treatment of cardiovascular and metabolic diseases.
GSK: 42.85 (+0.11)

Matinas BioPharma - "Lipidomics - An Exciting Foundation for Matinas BioPharma"
ACCESSWIRE - Wed Aug 06, 8:28AM CDT
New York, NY / August 6, 2014 / Matinas BioPharma (OTCBB:MTNB) published a new blog post today on The Chairman's Blog, written by the Company's President and Chief Executive Officer, Mr. Roelof Rongen. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.

Matinas BioPharma Launches Digital Corporate Communication Channels
GlobeNewswire - Thu Jul 31, 7:09AM CDT
Matinas BioPharma Holdings, Inc. ("Matinas BioPharma" or the "Company" (OTCBB:MTNB), an emerging biopharmaceutical company focused on the development and commercialization of omega-3 fatty acid-based prescription therapeutics for the treatment of cardiovascular and metabolic conditions, announced today a suite of online corporate communication channels to maintain on-going and direct communication with shareholders and other interested parties. The Company has launched official digital portals on social medial channels including Facebook, Twitter, LinkedIn, Google+, and The Chairman's Blog.

Matinas BioPharma Holdings, Inc. Common Stock Commences Trading on OTCBB Under Ticker Symbol MTNB
Marketwire - Tue Jul 22, 7:15AM CDT
Matinas BioPharma Holdings, Inc. ("Matinas BioPharma" or the "Company" (OTCBB: MTNB), an emerging biopharmaceutical company focused on the development and commercialization of omega-3 fatty acid-based prescription therapeutics for the treatment of cardiovascular and metabolic conditions, announced today that its shares of common stock have initiated trading via the Over-the-Counter Bulletin Board (OTCBB) under the ticker symbol "MTNB."




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Cottage Grove Tests Holiday Demand Across Lake Norman

Updated Category News Views 125

Flour and foot traffic make a pretty honest little scoreboard. Cottage Grove Bakery is putting itself in front of Lake Norman shoppers twice on Saturday, November 21, while also taking Thanksgiving orders and laying groundwork for 2027 workplace and school visits. This is not a public-company earnings story, and nobody should pretend a tray of scones is a quarterly...

Continue Reading
Chord's $550 Million Exit Tightens Its Basin Focus

Updated Category News Views 83

One map pin just disappeared from Chord Energy’s corporate wall, and that matters more than the usual deal-closing confetti. Chord has completed the sale of its entire non-operated Marcellus position to POSCO International for $550 million in gross consideration. For shareholders in NASDAQ:CHRD, this is not a flashy new drilling story. It is a cleanup job, and sometimes...

Continue Reading
AMD Faces Fresh Scrutiny Over China Supply Exposure

Updated Category News Views 140

One nasty report can turn a chip giant’s supply chain into a flashing red light, and that is precisely the mess confronting Advanced Micro Devices investors this week. Shares fell more than 7.7% on November 19 after Hunterbrook Media published allegations involving China-linked sales, firmware and manufacturing relationships. Then, on November 20, shareholder-rights...

Continue Reading
Allooloo's 100M Calls Test Capital Markets AI Data

Updated Category News Views 160

Forty-one point nine thousand issuers is a lot of financial clutter to keep straight, and Allooloo says its machines are getting called on to do precisely that at industrial scale. The Vancouver-based company reported on November 20 that its capital-markets data products now receive 100 million AI-agent calls a month—roughly 3.4 million daily, or 39 per second. That is...

Continue Reading
ASU's International Enrollment Lead Carries Real Weight

Updated Category News Views 125

Twenty thousand nine hundred twenty-six international students is not a campus footnote; it is a serious operating force moving through Arizona State University and the state around it. ASU has held the No. 1 spot among U.S. public universities hosting international students for six straight years, and the 2026 Open Doors report puts it No. 2 across public and private...

Continue Reading
S&P Global's December 8 Talk Puts Guidance in Focus

Updated Category News Views 71

A 35-minute fireside chat can be a whole lot of nothing, or it can leave a useful breadcrumb trail for shareholders willing to listen closely. S&P Global has put December 8, 2026 on the calendar, when Chief Executive Officer Martina Cheung is scheduled to appear at Goldman Sachs' 2026 Financial Services Conference in New York. Her slot runs from 5:00 p.m. to 5:35 p.m....

Continue Reading
Midterm Voters Put Cost Relief Ahead of Washington Wars

Updated Category News Views 100

Gas pumps and medical bills have a way of humiliating every grand political slogan ever printed. Seven Letter Insight's latest post-election survey says confirmed 2026 midterm voters want the 120th Congress to deal with costs first, particularly gas prices, health care, restoring health care tax credits and energy bills. That is not a glamorous mandate. It is, however,...

Continue Reading
Domino's Probe Puts Franchise Disclosure Under Lens

Updated Category News Views 110

A franchisee's shuttered stores can turn cheerful unit-growth talk into a nasty accounting of credibility, and that is the uncomfortable territory Domino's now occupies. Kahn Swick & Foti has opened an investigation into whether Domino's officers and directors breached fiduciary duties or violated state or federal law. That is not a finding of misconduct. It is a legal...

Continue Reading
Alibaba Lawsuit Deadline Puts Disclosure Risk in Focus

Updated Category News Views 169

A calendar deadline is doing more work than any earnings headline for Alibaba shareholders this week. A securities class action notice says investors who bought or acquired Alibaba Group Holding Limited securities between May 23, 2024 and November 11, 2026 may seek appointment as lead plaintiff by January 19, 2027. That is a procedural milestone, not a verdict, and...

Continue Reading
ModuleMD Takes Allergy EHR AI Beyond the Usual Hype Cycle

Updated Category News Views 84

Allergy Workflows Are Where This Has to Earn Its Keep Allergy clinics do not need another shiny dashboard clogging up a workstation. They need less typing, fewer handoffs, cleaner documentation, and fewer administrative chores slipping through the cracks while a packed day keeps moving. That is the practical lens for ModuleMD's ACAAI 2026 presentation in Phoenix: not...

Continue Reading

Top 5 Most Recently Viewed Articles

Exciting Funding Opportunity for Cartier Silver Corporation

Updated Category News Views 136

Cartier Silver Corporation Announces Financing Initiative Cartier Silver Corporation (CSE: CFE) has exciting news that emphasizes its commitment to growth and exploration. The Company is moving forward with a non-brokered private placement, intending to raise up to $1.5 million. Details of the Private Placement Under the terms of this Private Placement, Cartier Silver...

Continue Reading
Dynex Capital, Inc. Announces Exciting Dividend Updates

Updated Category News Views 56

Dynex Capital, Inc. Dividend Updates Dynex Capital, Inc. has recently made some important announcements regarding its dividends. The Board of Directors declared a cash dividend of $0.13 per share on its Common Stock (NYSE: DX) for September. Additionally, they revealed a quarterly cash dividend of $0.43125 per share for the 6.900% Series C Fixed-to-Floating Rate...

Continue Reading
Innovative Detox Solution to Alleviate Pain and Stress

Updated Category News Views 163

Introducing an Innovative Detox Solution In a world where wellness and self-care are becoming increasingly essential, an inventive product named TREETOX has emerged, aiming to redefine the way we think about detoxification and pain relief. Invented by a visionary in Pittsburgh, this product presents a seamless alternative for individuals battling ADHD and autism who are...

Continue Reading
WesBanco, Inc. Appoints Amby Bauer as Market President

Updated Category News Views 174

WesBanco, Inc. Names Amby Bauer as Western Pennsylvania Market President WesBanco, Inc. (NASDAQ: WSBC), a prominent multi-state banking institution, has announced the appointment of Amby Bauer as the new Western Pennsylvania Market President and Senior Commercial Banker. This strategic move comes at a time when the bank is focusing on enhancing its service provisions in...

Continue Reading
Svitzer Group Reports Major Shareholder Update from Morgan Stanley

Updated Category News Views 268

Svitzer Group Announces Major Shareholder Update In a significant development, Svitzer Group A/S has received a noteworthy notification concerning major shareholder dealings. The global leader in towage and marine services, Svitzer Group, confirmed a recent communication from Morgan Stanley regarding their shareholdings. As of a specified date, Morgan Stanley reportedly...

Continue Reading